Binosto®
The First and Only Buffered Solution for the Treatment of Osteoporosis
Alkindi®
Pediatric-Adapted Therapy for Adrenal Insufficiency
Efmody®
Treatment for Congenital Adrenal Hyperplasia
Miglustat Dipharma®
Oral Treatment for Gaucher Disease and Niemann-Pick Type C
Niemann-Pick Disease Type C
Congenital Adrenal Hyperplasia
Adrenal Insufficiency
Osteoporosis
EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines
Freienbach, February 6, 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced
EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States
Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced
